{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02290886",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CeTMAd/ELA/2011"
      },
      "Organization": {
        "OrgFullName": "Andalusian Network for Design and Translation of Advanced Therapies",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral",
      "OfficialTitle": "A Multicenter Phase I/II Clinical Trial, Randomized, Controlled With Placebo, Triple Blind to Evaluate Safety, and Indications of Efficiency of the Intravenous Administration of the Therapy With 3 Doses of MSC in Patients With ASL Moderated to Severe"
    },
    "StatusModule": {
      "StatusVerifiedDate": "July 2021",
      "OverallStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "July 2014"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "February 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "October 9, 2014",
      "StudyFirstSubmitQCDate": "November 11, 2014",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "November 14, 2014",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "July 21, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "July 22, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Iniciativa Andaluza en Terapias Avanzadas",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "A multicenter phase I/II Clinical trial,randomized, controlled with placebo, triple blind to evaluate the safety of the intravenous administration of 3 doses of autologous mesenchymal stem cells cells from adipose tissue in patients with Amyotrophic Lateral Sclerosis (ALS).",
      "DetailedDescription": "A multicenter phase I/II Clinical trial,randomized, controlled with placebo, triple blind to evaluate the safety of the intravenous administration of 3 doses of autologous mesenchymal stem cells cells from adipose tissue in patients with Amyotrophic Lateral Sclerosis (ALS).\n\n40 patients will be enrolled and will be randomized into one of the following 4 arms:\n\n10 patients in the control group (placebo)\n10 patients received a dose of 1 million MSC / kg\n10 patients received a dose of 2 million MSC / kg.\n10 patients received a dose of 4 million MSC / kg\n\nThe follow-up phase of each patient from the cell infusion/placebo will be 6 months.\n\nAt the time that each patient completed the follow-up period (i.e., 6 months after the infusion of the cellular product or placebo), the blind will be open, and patients who have been assigned to the control group, will receive the cell product as secondary treatment. These patients will be randomized to receive each of the doses used in the first phase. From this point, they begin a second period of follow up of 6 months.\n\nIn addition, after 6 months of MSC infusion, every patient will continue in an open extension study for 36 months to assess the safety of MSC."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Amyotrophic Lateral Sclerosis"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "safety evaluation",
          "intravenous administration",
          "3 doses of autologous MSC",
          "ALS"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Triple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "52",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Placebo",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Intravenous administration of placebo",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Intravenous administration of placebo"
              ]
            }
          },
          {
            "ArmGroupLabel": "1 million of MSC",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Intravenous administration of 1 million of MSC/ kg",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Intravenous administration of 1 million of MSC"
              ]
            }
          },
          {
            "ArmGroupLabel": "2 million of MSC",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Intravenous administration of 2 million of MSC/ kg",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Intravenous administration of 2 million of MSC"
              ]
            }
          },
          {
            "ArmGroupLabel": "4 million of MSC",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Intravenous administration of 4 million of MSC/ kg",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Intravenous administration of 4 million of MSC"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Other",
            "InterventionName": "Intravenous administration of placebo",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Intravenous administration of 1 million of MSC",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "1 million of MSC"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Intravenous administration of 2 million of MSC",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "2 million of MSC"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Intravenous administration of 4 million of MSC",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "4 million of MSC"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number of adverse serious unexpected reactions or not, attributable to the treatment (SUSSARs or SAE)",
            "PrimaryOutcomeDescription": "To evaluate the safety of the intravenous administration of 3 doses of autologous mesenchymal stem cells (MSC) from adipose tissue in patients with Amyotrophic lateral Sclerosis (ALS) ABSENCE of: complications in the place of the infusion, appearance of a new neurological effect not attributable to the natural progression of this pathology and adverse serious unexpected reactions or not, attributable to the treatment (SUSSARs or SAE)",
            "PrimaryOutcomeTimeFrame": "6 months"
          },
          {
            "PrimaryOutcomeMeasure": "Complications in the place of the infusion",
            "PrimaryOutcomeDescription": "To evaluate the safety of the intravenous administration of 3 doses of autologous",
            "PrimaryOutcomeTimeFrame": "6 months"
          },
          {
            "PrimaryOutcomeMeasure": "Appearance of a new neurological effect not attributable to the natural progression of this pathology",
            "PrimaryOutcomeDescription": "To evaluate the safety of the intravenous administration of 3 doses of autologous",
            "PrimaryOutcomeTimeFrame": "6 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Changes in the progression of the disease (modifications in the scale of functionality of the ALS)",
            "SecondaryOutcomeTimeFrame": "6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Changes in the degree of muscular force",
            "SecondaryOutcomeTimeFrame": "6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Changes in the vital forced capacity",
            "SecondaryOutcomeTimeFrame": "6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Changes of the muscular mass estimated by Nuclear Magnetic Resonance (NMR) of the upper and low extremities",
            "SecondaryOutcomeTimeFrame": "6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Changes in neurophysiological parameters and of quality of life",
            "SecondaryOutcomeTimeFrame": "6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Need and time to tracheotomy or permanent assisted ventilation",
            "SecondaryOutcomeTimeFrame": "6 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nWomen and males over 18-year-old.\nGood understanding of the protocol and aptitude to grant the informed assent.\nDiagnosis of sporadic ALS, with diagnosis of certainty, that is to say, definite or probable, in agreement with the criteria of \"El Escorial\", of the World Federation of Neurology.\nForced vital capacity of at least 50 % of the one that would correspond to them for sex, height and age.\nMore than 6 and less than 36 months of evolution of the disease (from the beginning of the symptoms).\nPossibility of obtaining, at least, 50gr of adipose tissue.\nTreatment with riluzole, for at least, a month before the inclusion.\n\nExclusion Criteria:\n\nAny concomitant disease that under investigator's criteria could concern the measures of the clinical variables of the trial (hepatic, renal or cardiac insufficiency, diabetes mellitus, etc).\nPrevious therapy with stem cells.\nParticipation in another clinical trial during 3 months previous to the entry in this trial.\nAny disease lymphoproliferative\nTracheostomy and /or gastrostomy.\nHaemophilia, diathesis hemorrhagic or anticoagulative current therapy.\nHypersensitivity known to the bovine foetal whey or the gentamicin.\nMedical precedents of infection of the HIV or any serious condition of immunocompromised.\nPositive HBV or HCV serology\nLevels of creatinine in whey > 3.0 in subjects not submitted to haemodialysis.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Óscar Fernández, MD",
            "OverallOfficialAffiliation": "Hospital Regional U. de Málaga",
            "OverallOfficialRole": "Study Chair"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Hospital Regional Universitario Reina Sofía",
            "LocationCity": "Cordoba",
            "LocationZip": "14004",
            "LocationCountry": "Spain"
          },
          {
            "LocationFacility": "Hospital Regional Universitario de Málaga",
            "LocationCity": "Málaga",
            "LocationZip": "29010",
            "LocationCountry": "Spain"
          },
          {
            "LocationFacility": "Hospital Universitario Virgen Macarena, Servicio de Neurología",
            "LocationCity": "Seville",
            "LocationZip": "41009",
            "LocationCountry": "Spain"
          },
          {
            "LocationFacility": "Hospital Universitario Virgen del Rocío",
            "LocationCity": "Seville",
            "LocationZip": "41013",
            "LocationCountry": "Spain"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "28674982",
            "ReferenceType": "derived",
            "ReferenceCitation": "Ilieva H, Maragakis NJ. Motoneuron Disease: Clinical. Adv Neurobiol. 2017;15:191-210. doi: 10.1007/978-3-319-57193-5_7. Review."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000016472",
            "ConditionMeshTerm": "Motor Neuron Disease"
          },
          {
            "ConditionMeshId": "D000000690",
            "ConditionMeshTerm": "Amyotrophic Lateral Sclerosis"
          },
          {
            "ConditionMeshId": "D000012598",
            "ConditionMeshTerm": "Sclerosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000019636",
            "ConditionAncestorTerm": "Neurodegenerative Diseases"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000009468",
            "ConditionAncestorTerm": "Neuromuscular Diseases"
          },
          {
            "ConditionAncestorId": "D000013118",
            "ConditionAncestorTerm": "Spinal Cord Diseases"
          },
          {
            "ConditionAncestorId": "D000002493",
            "ConditionAncestorTerm": "Central Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000057177",
            "ConditionAncestorTerm": "TDP-43 Proteinopathies"
          },
          {
            "ConditionAncestorId": "D000057165",
            "ConditionAncestorTerm": "Proteostasis Deficiencies"
          },
          {
            "ConditionAncestorId": "D000008659",
            "ConditionAncestorTerm": "Metabolic Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M14567",
            "ConditionBrowseLeafName": "Sclerosis",
            "ConditionBrowseLeafAsFound": "Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M18031",
            "ConditionBrowseLeafName": "Motor Neuron Disease",
            "ConditionBrowseLeafAsFound": "Lateral Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3176",
            "ConditionBrowseLeafName": "Amyotrophic Lateral Sclerosis",
            "ConditionBrowseLeafAsFound": "Amyotrophic Lateral Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M20711",
            "ConditionBrowseLeafName": "Neurodegenerative Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11563",
            "ConditionBrowseLeafName": "Neuromuscular Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M15067",
            "ConditionBrowseLeafName": "Spinal Cord Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4894",
            "ConditionBrowseLeafName": "Central Nervous System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M27912",
            "ConditionBrowseLeafName": "TDP-43 Proteinopathies",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M27900",
            "ConditionBrowseLeafName": "Proteostasis Deficiencies",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10791",
            "ConditionBrowseLeafName": "Metabolic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T4699",
            "ConditionBrowseLeafName": "Primary Lateral Sclerosis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T349",
            "ConditionBrowseLeafName": "Amyotrophic Lateral Sclerosis",
            "ConditionBrowseLeafAsFound": "Amyotrophic Lateral Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC18",
            "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}